Arena Pharmaceuticals, Inc. (ARNA) Stock

About Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing innovative therapeutic agents, specifically designed with distinct pharmacological and pharmacokinetic profiles, for a global patient population. Its extensive pipeline features several key investigational medicines. Etrasimod (APD334) is undergoing diverse clinical evaluations, including a Phase III study for ulcerative colitis, a Phase IIb/III trial for Crohn's disease, a Phase II trial for alopecia areata, a separate Phase III trial for atopic dermatitis, and a Phase IIb study for eosinophilic esophagitis. Olorinab (APD371) is currently in a Phase IIb clinical trial, targeting abdominal discomfort linked to irritable bowel syndrome. APD418 is progressing through Phase II trials for acute heart failure, while Temanogrel is also in Phase II development, addressing coronary microvascular obstruction. Furthermore, Ralinepag (APD811) is undergoing Phase III clinical assessment for pulmonary arterial hypertension. Arena maintains collaborative alliances with a range of entities, such as United Therapeutics Corporation, Everest Medicines Limited, Eisai Co., Ltd. and Eisai Inc., Boehringer Ingelheim International GmbH, Beacon Discovery, Inc., and Aristea Therapeutics, Inc. Established in 1997, Arena Pharmaceuticals, Inc. operates from its headquarters in Park City, Utah. As of March 11, 2022, the company functions as a subsidiary of Pfizer Inc.

the stock is valued at a price-to-earnings (P/E) ratio of -8.83, price-to-book of 8.13, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $99.97 and $100.00, and currently trades at its 52-week high.

On profitability, Arena Pharmaceuticals, Inc. generates a return on equity (ROE) of -92.27%, return on capital employed of -85.23%.

Official website: www.arenapharm.com